Cancer Genetics Inc (CGIX) 2.03 $CGIX Cancer Genetics,

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 7:09 AM

Cancer Genetics Inc (CGIX) 2.03 $CGIX

Cancer Genetics, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Updates
GlobeNewswire - Tue Aug 09, 5:59PM CDT
-- Company Reports Quarterly Revenues of $7 million, an increase of 67% over the Second Quarter of 2015
CGIX: 2.03 (-0.13)

Healthcare Stocks' Q2 Earnings on Aug 10: QHC, CDNA & CGIX
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 6:52AM CDT
Here, we take a look at three healthcare stocks scheduled to report their second-quarter figures on Aug 10.
CDNA: 4.66 (-0.13), QHC: 6.15 (-0.05), CGIX: 2.03 (-0.13)

Cancer Genetics to Report Second Quarter Earnings on Wednesday, August 10
GlobeNewswire - Mon Aug 01, 4:00PM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the second quarter on Wednesday, August 10, 2016. The company and key management team members will also hold a live investor conference call and webcast at 8:30 AM Eastern on Wednesday, August 10 2016 to discuss the financial results and company updates.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI's Proprietary FDA-cleared Tissue of Origin (TOO(R)) Test Throughout India and South Asia
GlobeNewswire - Thu Jun 23, 7:25AM CDT
-- TOO(R) is the ONLY FDA-cleared test of its type, used to aid in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference
GlobeNewswire - Tue Jun 07, 6:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at LD Micro's Sixth Invitational Conference on Wednesday, June 8, 2016 at 11:00 AM Pacific Time, at the Luxe Sunset Bel Air in Los Angeles, CA.
CGIX: 2.03 (-0.13)

HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ("HTG"

, a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI"

, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3-7, 2016 in Chicago, IL.
HTGM: 2.50 (-0.01), CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Partners with ArcherDX to Offer Archer(R) NGS Assays as a Sequencing Service for Biotech and Pharma
BusinessWire - Thu Jun 02, 7:51AM CDT
ArcherDX, Inc., a leader in NGS-based gene fusion detection, has announced that Cancer Genetics, Inc., (CGI) has become a Certified Service Provider of Archer(R) FusionPlex(R) NGS assays. Additionally, CGI plans to use Archer VariantPlex(TM) assays to identify copy number variants (CNVs) and point mutations in tumor samples and will be testing these assays in cell-free variant detection.
CGIX: 2.03 (-0.13)

Cancer Genetics Announces $5 Million Registered Direct Offering
GlobeNewswire - Fri May 20, 8:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("Cancer Genetics" or the "Company"

, an emerging leader in DNA-based cancer diagnostics, today announced that it has entered into definitive agreements with healthcare focused institutional investors for an offering of 2.5 million shares of common stock with gross proceeds of approximately $5 million in a registered direct offering.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel in Precision Medicine, FOCUS::Lymphoma (TM)
GlobeNewswire - Tue May 17, 6:30AM CDT
-- FOCUS::Lymphoma(TM) panel is being used to power several clinical trials with biotech and pharmaceutical companies, and is now available for use in a clinical setting
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Announces 39% Revenue Increase and Provides Recent Company Highlights
GlobeNewswire - Tue May 10, 4:06PM CDT
-- Company reports record quarterly revenues of $6.1 million, an increase of 39% over Q1 2015 and 11% over Q4 2015
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. to Present at Pioneers 2016 Conference Presented by Joseph Gunnar & Co., LLC
GlobeNewswire - Thu May 05, 6:14AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the Pioneers 2016 Conference presented by Joseph Gunnar & Co., LLC on Thursday, May 5, 2016 at 8:30 AM Eastern Time, at the New York Palace Hotel in New York City.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies
GlobeNewswire - Wed May 04, 7:34AM CDT
-- CGI is uniquely positioned to deliver comprehensive immune marker and genomic data in oncology for biopharma partners and clinical centers for both solid and blood cancers
CGIX: 2.03 (-0.13)

Cancer Genetics to Report First Quarter 2016 Financial Results on Tuesday, May 10th
GlobeNewswire - Tue May 03, 6:36PM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 after the market close on Tuesday, May 10, 2016. The company will also hold a live investor conference call and webcast at 5:00 pm Eastern.
CGIX: 2.03 (-0.13)

Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota
GlobeNewswire - Fri Feb 05, 7:00AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Minnesota ("BCBS of Minnesota"

. As part of the agreement, the over 2.6 million members of the Blue Cross Blue Shield plan will have access to CGI's cancer diagnostics and genomic testing services.
CGIX: 2.03 (-0.13)

Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use In Clinical Trials, Translational Research, and Therapy Selection For Patients
M2 - Fri Jan 22, 4:20AM CST
* Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients
CGIX: 2.03 (-0.13)

Molecular Diagnostics in Cancer Testing 2016 - New Technologies and Applications Being Continually Added
M2 - Wed Jan 13, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/2m62l5/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" report to their offering. Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned - Abbott Molecular Diagnostics - Accugenomics, Inc. - Agendia - Ambry Genetics - Biodesix - bioM?rieux - bioTheranostics (AviaraDx) - Cancer Genetics, Inc. - Clarient, Inc. (GE Healthcare) - Counsyl - Flatiron Health - Epigenomics - Exact Sciences Corporation - Exiqon - Genomic Health, Inc. - Genoptix, Inc. (Novartis) - Genmark Diagnostics - Genomictree - HTG Molecular Diagnostics - Invitae - LabCorp - Myriad Genetics, Inc. - Nanostring - Neogenomics - NSTG - Nuvera Biosciences - Orion Genomics - Pathway Genomics - Personal Genome Diagnostics - Quest Diagnostics - Rosetta Genomics Ltd. - Signal Genetics - Source MDx - Wilex, Inc. For more information visit http://www.researchandmarkets.com/research/2m62l5/molecular
SGNL: 0.47 (unch), MYGN: 20.36 (-0.18), DGX: 82.82 (-0.72), HTGM: 2.50 (-0.01), EXAS: 18.47 (-0.46), GHDX: 26.47 (+0.31), CGIX: 2.03 (-0.13), NVS: 78.77 (-0.57)

Cancer Genetics, Inc. (CGI) to Present Results of Collaborative Renal Biopsy and Clear Cell Renal Cell Carcinoma (ccRCC) Studies at the 2016 Genitourinary Cancer Symposium
GlobeNewswire - Wed Jan 06, 5:22PM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics announced the presentation of results from collaborative studies with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. The first study focuses on actionable diagnostic and prognostic information provided by CGI's proprietary next-generation sequencing panel using renal cancer biopsies. The second study focuses on identification of somatic variants in metastatic clear cell renal cell carcinoma patients. Posters with results of both studies will be presented during the 2016 Genitourinary Cancers Symposium, on January 7-9, 2016 in San Francisco, CA.
CGIX: 2.03 (-0.13)

New Strong Sell Stocks for January 6th
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BCC: 26.24 (-0.51), CARO: 21.45 (-0.87), ACBI: 15.41 (+0.02), CGIX: 2.03 (-0.13), HRB: 21.66 (-2.54)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

New Tools Arm Manufacturers in Additive Arena

Diving Headfirst into Additive Manufacturing Standards Additive manufacturing (AM)—it's not just another tech buzzword. It's revolutionizing everything from life-saving medical devices to cutting-edge aerospace components. But as with any game-changing innovation, there's a wild west era before standards reign in the chaos. Enter ANSI and America Makes, offering new...

Mitsubishi's Q3 Sales: SUVs Up, Mirage Out

You ever notice how the market treats innovation and tradition like they’re these ever-spinning plates in a circus act? Take Mitsubishi Motors North America (MMNA). Their third-quarter report's got me both nodding in approval and scratching my head. Sure, they sold 18,543 vehicles—down 5.6% from the previous year. But don’t write 'em off just yet. The slumping...

Sports Research Joins Costco: Creatine Mix Available

Breaking Into the Big League: Sports Research Hits Costco When a company's product finds its way onto Costco's shelves, you know they're not just playing in the minor leagues anymore. This October, Sports Research® made a bold move into the retail giant's sports nutrition section with their new Creatine + Electrolytes powder. It's not their first rodeo when it comes to...

Cannatrol and Veterans Nonprofit Unite for Healing

Veterans Find a New Ally in Cannabis Tech When two distinct worlds collide for a cause, it can create waves of change much bigger than simple collaboration. That's exactly what's happening with Cannatrol and Operation Green Healing, a partnership that could redefine support for our veterans. Cannatrol, renowned for its groundbreaking post-harvest cannabis technology, has...

Wisconsin Chefs Transform Pizza with Crave Brothers Cheese

Reimagining Pizza with Wisconsin's Best Cheeses It's not every day you see a pizza challenge that turns a staple of Friday nights into a gastronomic showcase. But that's exactly what's happening in Wisconsin as chefs flex their creativity using Crave Brothers Farmstead Cheese. This is no ordinary cheese-and-pepperoni affair—these culinary pros are cooking up pizzas with...

Quorum Joins LIVE Coalition to Revolutionize Estate Planning

Shaking Up Estate Planning: Quorum Joins LIVE Coalition Here's a fresh shake-up in the world of estate planning. Quorum Federal Credit Union has thrown its hat into the ring as the latest member of the LIVE Coalition, a band of financial, legal, and tech wizards putting estate plans on a modern track. This marks them as the 70th player to dive into this alliance, pushing...

Ultrabench Revolutionizes AI Model Comparison Game

Breaking Down the Messy AI Model Landscape Ultrabench.ai is here to drag AI model comparison out of the dark ages. Picture this: 309 AI models, ranked against a whopping 530 benchmarks, all served up on one plate. If you’re navigating the AI jungle, you’ll realize how Ultrabench is no small fish in this vast ocean. Consolidating Where Others Have Scattered There's a...

Gateway Unveils All-In-One Award Travel Platform

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

Maternal Health Index: A New Tool With Big Ambitions

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...